A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 143
- Population
- ALL · 70 Years
- Duration
- 2014-06-09 to 2017-07-14
- Intervention
- nab-paclitaxel; Carboplatin
- Comparator
- Not reported
- Outcomes measured
- Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade…; Number of Participants With Treatment Emergent Adverse Events During the Treatment Period — From the date of the first…; Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn —…; Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study — From day 1 of study treatment to the end date of st…; Dose Intensity Per Week of Carboplatin During the Entire Study — From day 1 of study treatment to the end date of study…; Percentage of Participants With Dose Reductions During the Entire Study — From the first dose of study treatment to dis…; Percentage of Participants With a Dose Delay During the Entire Study — From the first dose of study treatment to discon…; Kaplan Meier Estimate of Progression-Free Survival (PFS) — From first dose of IP to the date of disease progression; up…; Kaplan Meier Estimate of Overall Survival (OS) — From first dose of IP to the date of death due to any cause; up to a l…; Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) Acco…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cancer and ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.